In the first half of 2023, growth shares – and as such, also the biotechnology sector – came under pressure as investors were pivoting towards value shares. But the signs are changing. The possible high in interest rates in Europe and the USA could boost biotech shares again, as ERSTE STOCK BIOTEC fund manager Harald Kober explains in an interview.
Biotechnology shares have seen better times. Despite the most recent corrections, hopes for growth in the biotechnology sector remain very high. We spoke to Harald Kober, fund manager of ERSTE STOCK BIOTEC, about the latest developments.
The corona virus has a lock on the economy and the stock exchanges. Tests by the US pharmaceutical group Gilead in its search for a suitable remedy to fight the pandemic may be cause for hope. Harald Kober, senior fund manager of the equity fund ERSTE STOCK BIOTEC, keeps this company in the portfolio and has noticed a global increase in healthcare investments.
Healthcare has never been so important as it is today. Which changed living and consumption habits will influence our future the most?
Biotechnology stocks are among the stocks with the highest growth potential. What can they do and why are they on everyone’s lips? Read on here!
Biotechnology shares have been among the top performers in the past ten years. After the above-average performance from 2010 to the beginning of 2015, hedge funds set off a consolidation that is now coming to an end. The NASDAQ biotechnology index, the most important barometer for biotech shares, has gained 25% in the year to date (source: Reuters Datastream, as of 31 August 2017).
